Next Article in Journal
Differential Expression of CD31 and Von Willebrand Factor on Endothelial Cells in Different Regions of the Human Brain: Potential Implications for Cerebral Malaria Pathogenesis
Next Article in Special Issue
Development and Evaluation of a Screening Tool to Aid the Diagnosis of Cluster Headache
Previous Article in Journal
The Use of Hyperscanning to Investigate the Role of Social, Affective, and Informative Gestures in Non-Verbal Communication. Electrophysiological (EEG) and Inter-Brain Connectivity Evidence
Previous Article in Special Issue
Anoctamin 3: A Possible Link between Cluster Headache and Ca2+ Signaling

Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache

Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden
Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, 221 84 Lund, Sweden
Department of Clinical Experimental Research, Glostrup Research Institute, Rigshospitalet Glostrup, 2600 Glostrup, Denmark
Authors to whom correspondence should be addressed.
Brain Sci. 2020, 10(1), 30;
Received: 14 December 2019 / Revised: 28 December 2019 / Accepted: 30 December 2019 / Published: 6 January 2020
(This article belongs to the Special Issue Recent Advances and New Insights in Cluster Headache)
Cluster headache (CH) is a severe primary headache with a prevalence of 1/1000 individuals, and a predominance in men. Calcitonin gene-related peptide (CGRP) is a potent vasodilator, originating in trigeminal neurons and has a central role in CH pathophysiology. CGRP and the CGRP receptor complex have recently taken center stage as therapeutic targets for primary headaches, such as migraine. Multiple CGRP and CGRP receptor monoclonal antibodies, as well as small molecule antagonists (gepants) are on their way constituting a new frontier of migraine and possibly CH medication. During a CH attack, there is an activation of the trigeminal-autonomic reflex with the release of CGRP, and inversely if CGRP is administered to a CH patient in an active disease phase, it triggers an attack. Increased levels of CGRP have been found in ipsilateral jugular vein blood during the active phase of CH. This process is hypothesized to have a key role in the intense pain perception and in the associated distinctive vasodilation. So far, clinical tests of CGRP antibodies have been inconclusive in CH patients. This review summarizes the current state of knowledge on the role of CGRP in CH pathology, and as a target for future treatments. View Full-Text
Keywords: neurovascular; receptor; vasodilator; antibodies; genetics neurovascular; receptor; vasodilator; antibodies; genetics
Show Figures

Figure 1

MDPI and ACS Style

Carmine Belin, A.; Ran, C.; Edvinsson, L. Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache. Brain Sci. 2020, 10, 30.

AMA Style

Carmine Belin A, Ran C, Edvinsson L. Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache. Brain Sciences. 2020; 10(1):30.

Chicago/Turabian Style

Carmine Belin, Andrea, Caroline Ran, and Lars Edvinsson. 2020. "Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache" Brain Sciences 10, no. 1: 30.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop